BioVie Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $16.4M
- Price
- $2.23
- % Change (Daily % change from the live per-ticker quote feed.)
- +2.29%
- Volume
- 58.5K
Quote data as of 6:13 AM ET
About
BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis. Additionally, BioVie is advancing NE3107, which is currently undergoing a Phase III clinical trial for the management of mild to moderate Alzheimer's disease, and is also in a Phase I clinical trial for the treatment of Parkinson's disease. Further preclinical investigations are underway for NE3107, exploring its potential applications in treating multiple myeloma and prostate cancer. Established in 2013, the company adopted its current name, BioVie Inc., in July 2016, having previously operated as NanoAntibiotics, Inc. Its corporate headquarters are situated in Carson City, Nevada.
Quick stats
Shares outstanding7.5M
Computed float7.1M
Float sourceUnknown
Cash runway (months)Unknown
Dilution risk—
Has warrants—
Has convertibles—
Active shelf (Shelf registration (e.g. Form S-3) currently in effect — the company is pre-cleared to issue and sell new shares quickly. A standing dilution risk.)—
Active ATM (At-the-market offering — a program to sell newly issued shares directly into the open market at prevailing prices, diluting existing holders over time.)—
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001580149
Websitehttps://bioviepharma.com
AI Summary
AI-generated1mo agominorneutrallegal litigationDid BioVie Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Halper Sadeh LLC issued a press release stating it is investigating whether BioVie insiders breached fiduciary duties.
The release solicits shareholders to contact the firm to discuss their rights on a contingency fee basis.
This is a routine plaintiff-firm marketing notice, not an issuer disclosure or court filing.